menu
    • menu

    Company profile for Samsung Bioepis

    NEW Drugs in Dev: 19
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines through the development of biosimilars.
    Samsung Bioepis is advancing an extensive pipeline of biosimilar candidates through process innovation and an unwavering commitment to quality.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Samsung Bioepiskorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    107, Cheomdan-daero, Yeonsu-gu, Incheon
    Telephone
    Telephone
    +82 - 32 - 455 - 6114
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.samsungbioepis.com/en/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/samsung-bioepis
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Samsung Bioepis Launches OPUVIZ Aflibercept Vial in Europe
    Samsung Bioepis Launches OPUVIZ Aflibercept Vial in Europe

    30 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260528005232/en/Samsung-Bioepis-Launches-OPUVIZ-Aflibercept-40-mgmL-Vial-Across-Europe-to-Treat-Ophthalmic-Conditions

    BUSINESSWIRE
    30 May 2026
    Share Share
    Samsung Bioepis Launches Ustekinumab Biosimilar in Japan
    Samsung Bioepis Launches Ustekinumab Biosimilar in Japan

    20 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7449874

    FIRSTWORD PHARMA
    20 May 2026
    Share Share
    Cartography Bio Gets Strategic Investment from Samsung Ventures
    Cartography Bio Gets Strategic Investment from Samsung Ventures

    06 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260506478576/en/Cartography-Biosciences-Announces-Strategic-Investment-From-Samsung-Ventures-to-Advance-Oncology-Pipeline

    BUSINESSWIRE
    06 May 2026
    Share Share
    Samsung Bioepis' Pembrolizumab Biosimilar SB27 Meets PK Endpoints
    Samsung Bioepis' Pembrolizumab Biosimilar SB27 Meets PK Endpoints

    06 May 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/biopharma/samsung-bioepis-pembrolizumab-biosimilar-sb27-meets-phase-1-pk-endpoints-20082

    INDPHARMAPOST
    06 May 2026
    Share Share
    Samsung Bioepis, ATLATL Sign MoU to Boost APAC Biotech
    Samsung Bioepis, ATLATL Sign MoU to Boost APAC Biotech

    28 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260428924789/en/Samsung-Bioepis-and-ATLATL-Sign-Memorandum-of-Understanding-MoU-to-Accelerate-Early-Stage-Biotech-Innovation-in-Asia-Pacific

    BUSINESSWIRE
    28 Apr 2026
    Share Share
    Samsung Bioepis Report: Biosimilars Surge With 92 US Approvals
    Samsung Bioepis Report: Biosimilars Surge With 92 US Approvals

    28 Apr 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/biopharma/biosimilars-gain-momentum-as-us-market-sees-92-approvals-samsung-bioepis-report-19950

    INDPHARMAPOST
    28 Apr 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search